Evolution of FMT – From early clinical to standardized treatments

Stephanie L. Servetas; Phillip J. Daschner; Cyril Guyard; Vincent Thomas; Herve Affagard; Chrysi Sergaki; Harry Sokol; Jennifer A. Wargo; Gary D. Wu; Philippe Sabot

doi:10.1016/j.biologicals.2022.01.004

Evolution of FMT – From early clinical to standardized treatments

Stephanie L. Servetas, Phillip J. Daschner, Cyril Guyard, Vincent Thomas, Herve Affagard, Chrysi Sergaki, Harry Sokol, Jennifer A. Wargo, Gary D. Wu, Philippe Sabot

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Faecal microbiota transplantation (FMT) is widely reported to be an effective treatment against recurrent Clostridioides difficile infections. Recent clinical studies support the therapeutic use of FMT for several other pathologies including inflammatory bowel disease, several types of cancer, and other functional or metabolic disorders. Initial guidelines are now available to overcome some of the technical and logistical issues for establishing a non-standardized treatment into clinical practice with proper safety and governance. To aid the improvement of guidance and standardization requirements for FMT, the International Alliance for Biological Standardization (IABS) and the BIOASTER Microbiology Technology Institute hosted a joint online workshop in May of 2021. The goal of the webinar was to provide a multi-disciplinary perspective of the ongoing efforts to develop FMT guidelines including technical, regulatory, and standardization requirements. Recognized experts gave insights into state-of-the art approaches and standards developed by international organizations and institutions.

Original language	English (US)
Pages (from-to)	31-35
Number of pages	5
Journal	Biologicals
Volume	76
DOIs	https://doi.org/10.1016/j.biologicals.2022.01.004
State	Published - Apr 2022
Externally published	Yes

Keywords

Fecal microbiota standards
FMT
Standards

ASJC Scopus subject areas

Biotechnology
Bioengineering
Applied Microbiology and Biotechnology
General Immunology and Microbiology
Pharmacology

Access to Document

10.1016/j.biologicals.2022.01.004

Cite this

@article{1f27e7e353d046a3838e056ec77131fd,

title = "Evolution of FMT – From early clinical to standardized treatments",

abstract = "Faecal microbiota transplantation (FMT) is widely reported to be an effective treatment against recurrent Clostridioides difficile infections. Recent clinical studies support the therapeutic use of FMT for several other pathologies including inflammatory bowel disease, several types of cancer, and other functional or metabolic disorders. Initial guidelines are now available to overcome some of the technical and logistical issues for establishing a non-standardized treatment into clinical practice with proper safety and governance. To aid the improvement of guidance and standardization requirements for FMT, the International Alliance for Biological Standardization (IABS) and the BIOASTER Microbiology Technology Institute hosted a joint online workshop in May of 2021. The goal of the webinar was to provide a multi-disciplinary perspective of the ongoing efforts to develop FMT guidelines including technical, regulatory, and standardization requirements. Recognized experts gave insights into state-of-the art approaches and standards developed by international organizations and institutions.",

keywords = "Fecal microbiota standards, FMT, Standards",

author = "Servetas, {Stephanie L.} and Daschner, {Phillip J.} and Cyril Guyard and Vincent Thomas and Herve Affagard and Chrysi Sergaki and Harry Sokol and Wargo, {Jennifer A.} and Wu, {Gary D.} and Philippe Sabot",

note = "Publisher Copyright: {\textcopyright} 2022",

year = "2022",

month = apr,

doi = "10.1016/j.biologicals.2022.01.004",

language = "English (US)",

volume = "76",

pages = "31--35",

journal = "Biologicals",

issn = "1045-1056",

publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Evolution of FMT – From early clinical to standardized treatments

AU - Servetas, Stephanie L.

AU - Daschner, Phillip J.

AU - Guyard, Cyril

AU - Thomas, Vincent

AU - Affagard, Herve

AU - Sergaki, Chrysi

AU - Sokol, Harry

AU - Wargo, Jennifer A.

AU - Wu, Gary D.

AU - Sabot, Philippe

PY - 2022/4

Y1 - 2022/4

N2 - Faecal microbiota transplantation (FMT) is widely reported to be an effective treatment against recurrent Clostridioides difficile infections. Recent clinical studies support the therapeutic use of FMT for several other pathologies including inflammatory bowel disease, several types of cancer, and other functional or metabolic disorders. Initial guidelines are now available to overcome some of the technical and logistical issues for establishing a non-standardized treatment into clinical practice with proper safety and governance. To aid the improvement of guidance and standardization requirements for FMT, the International Alliance for Biological Standardization (IABS) and the BIOASTER Microbiology Technology Institute hosted a joint online workshop in May of 2021. The goal of the webinar was to provide a multi-disciplinary perspective of the ongoing efforts to develop FMT guidelines including technical, regulatory, and standardization requirements. Recognized experts gave insights into state-of-the art approaches and standards developed by international organizations and institutions.

AB - Faecal microbiota transplantation (FMT) is widely reported to be an effective treatment against recurrent Clostridioides difficile infections. Recent clinical studies support the therapeutic use of FMT for several other pathologies including inflammatory bowel disease, several types of cancer, and other functional or metabolic disorders. Initial guidelines are now available to overcome some of the technical and logistical issues for establishing a non-standardized treatment into clinical practice with proper safety and governance. To aid the improvement of guidance and standardization requirements for FMT, the International Alliance for Biological Standardization (IABS) and the BIOASTER Microbiology Technology Institute hosted a joint online workshop in May of 2021. The goal of the webinar was to provide a multi-disciplinary perspective of the ongoing efforts to develop FMT guidelines including technical, regulatory, and standardization requirements. Recognized experts gave insights into state-of-the art approaches and standards developed by international organizations and institutions.

KW - Fecal microbiota standards

KW - FMT

KW - Standards

UR - http://www.scopus.com/inward/record.url?scp=85123686646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123686646&partnerID=8YFLogxK

U2 - 10.1016/j.biologicals.2022.01.004

DO - 10.1016/j.biologicals.2022.01.004

M3 - Article

C2 - 35086768

AN - SCOPUS:85123686646

SN - 1045-1056

VL - 76

SP - 31

EP - 35

JO - Biologicals

JF - Biologicals

ER -

Evolution of FMT – From early clinical to standardized treatments

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this